On interest in SMG1, as well as NMD, as a therapeutic target for cancer [30,31] and findings that overexpression of p53β in advanced stage breast cancers is associated with better patient outcomes [32], we confirm that SMG1 knockdown increases p53β isoform protein with specific antibody. This evidence concerns the gene SMG1 and breast carcinoma.